Ventilator-associated pneumonia(VAP)and pleural empyema caused by multidrug-resistant Acinetobacter baumannii in HIV and COVID 19 infected patient:A case report  

作　　者：Rosa Anna Passerotto Francesco Lamanna Damiano Farinacci Alex Dusina Simona Di Giambenedetto Arturo Ciccullo Alberto Borghetti 

机构地区：[1]Dipartimento di Sicurezza e Bioetica-Sezione di Malattie Infettive,UniversitàCattolica del Sacro Cuore,00168 Rome,Italy [2]Dipartimento di Scienze di Laboratorio e Infettivologiche,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,00168 Rome,Italy [3]Infectious Diseases Unit,San Salvatore Hospital,67100 L’Aquila,Italy

出　　处：《Infectious Medicine》2023年第2期143-147,共5页感染医学（英文）

基　　金：This work was supported by internal funding.

摘　　要：We analyzed the case of a 49-year-old woman with HIV infection off-therapy with poor viro-immunological compensation,not vaccinated for SARS-COV-2,hospitalized for lobar pneumonia and severe COVID19-related respiratory failure in intensive care unit(ICU).The hospitalization was complicated by bacteraemic ventilator-associated pneumonia(VAP)caused by multidrug-resistant Acinetobacter baumannii(MDR-AB)isolated on pleural fluid culture,treated with colistin and cefiderocol for about 3 weeks.The molecular research of MDR-AB on transtracheal aspirate was negative following this therapy.The aim is to show the safety,efficacy and tolerability of colistin-based combination therapy with cefiderocol for Acinetobacter baumannii infection in HIV-infected patient.

关 键 词：Acinetobacter baumannii COLISTIN cefiderocol SARS-CoV-2 HIV 

分 类 号：R563.1[医药卫生—呼吸系统]